Headliner Stage 

LSX WELCOME
Josh Dance, Managing Director, LSX  

Entering a New Paradigm for Biotech and Healthcare Innovators

As 2023 draws to a close, the biotech sector continues to face a challenging landscape: public markets are still on the path to recovery, the IPO window remains narrow and private investors are exercising caution. However, there are reasons for optimism. Market fundamentals remain strong, and there are early signs of stabilization – possibly even improvements. Delivering insights on the current state of the biotech sector, highlighting the strategic implications for both investors and biotech firms, and addressing three central questions:

• What healthcare trends are shaping the industry, and how is the global biotech financing landscape evolving in response?
  
• How is investors' decision-making evolving, and how are biotech companies responding to these changes?
  
• What are the key priorities for biotech companies and investors for the next few years?

Alexandra Zemp, Partner, McKinsey 
Lisbeth Van Ruijssevelt, Associate Partner, McKinsey

A Complex Path Forward Or A Trail Ahead Full Of Opportunity? The Healthcare Markets In 2023 & Beyond - Expectations, Pressures, & Opportunities  

As we are knocking on the door of 2024 and preparing for another year ahead of investments, deals, and acquisitions, 2023 would have seen a total of 5 patent expirations of established biological products worth billions.

Potential innovation deficits must be addressed and new revenues found, while emerging biotechs continue to navigate a capital-constrained environment to meet the next value inflection point. Medtech faces it's own challenges with a drop in M&A dealmaking and capital raised, and pressure on R&D investments, while the broad encompassing healthtech and digital health space has seen continued investment in some areas and declined in others.  

A multi-stakeholder panel reviews and explores how they see these challenges and dynamics evolving and how investors, pharma and other key stakeholders see the dynamics evolving through into 2024 and beyond.   

• Recent trends within deal-making and investment industry - an increasing M&A appetite?  
• How are investors viewing late private and public biotechs with de-risked, late-stage assets among the impending wave of patent expirations?  
• Do we expect to see rebound a rebound in investment volume and deal sizes and the IPO market? Do we expect biotech, medtech and healthtech will fair different?  

Moderator: Eleanor Malone, Editor in Chief, Commercial Pharma Insights, Citeline
Regina Hodits, Managing Partner, Wellington Partners Life Sciences  
Geraldine O’Keefe, Partner, EQT Life Sciences  
Diana Saraceni, Managing Partner & Founder, Panakes Partners 
Gil Bar-Nahum, MD, Global Healthcare Investment Banking, Jefferies  
Michael Rice, Founding Partner, LifeSci Advisors